Simulations Plus (SLP) Akcija Цена

The main competitors of Simulations Plus Inc in the market include Certara, Inc and Dassault Systèmes.

The business model of Simulations Plus Inc revolves around providing software and consulting services for pharmaceutical research and development. As a leading provider in the field of drug discovery and development, Simulations Plus Inc aims to enhance the efficiency and effectiveness of the pharmaceutical industry through their innovative solutions. By utilizing computer modeling and simulation software, the company assists in predicting and optimizing drug properties, interactions, and outcomes. This enables scientists and researchers to make informed decisions throughout the drug development process, leading to improved efficacy, safety, and reduced costs. Simulations Plus Inc's comprehensive solutions cater to the needs of pharmaceutical companies, regulatory agencies, and academia worldwide.

Simulations Plus Inc is a leading provider of simulation and modeling software for the pharmaceutical and biotechnology industries. Established in 1996, the company has amassed extensive expertise in the field. Simulations Plus Inc has developed a strong reputation for its cutting-edge technology and innovative solutions, helping pharmaceutical companies optimize drug discovery and development processes. With a focus on increasing efficiency and reducing costs, Simulations Plus Inc has become a trusted partner for numerous organizations worldwide. The company's commitment to excellence has earned them recognition and a loyal customer base. Simulations Plus Inc continues to drive advancements in the industry, delivering impactful software solutions that streamline drug development.

Simulations Plus Inc has achieved significant milestones throughout its history. Some notable accomplishments include the development and release of their industry-leading software solutions, such as GastroPlus™ and DDDPlus™, which have gained widespread recognition and adoption in the pharmaceutical industry. The company has also formed strategic partnerships and collaborations with top pharmaceutical companies, further establishing its presence and credibility in the market. Additionally, Simulations Plus Inc has a strong track record of achieving consistent revenue growth and delivering value to its shareholders. These achievements reflect the company's commitment to innovation, excellence, and meeting the evolving needs of the life sciences industry.

Simulations Plus Inc is primarily present in the United States.

Simulations Plus Inc represents values of innovation, scientific excellence, and customer satisfaction. With a corporate philosophy focused on advancing pharmaceutical research and enhancing drug development, Simulations Plus Inc strives to provide cutting-edge software and consulting services. By combining advanced technologies and domain knowledge, the company facilitates cost-effective and efficient drug discovery and development processes. Simulations Plus Inc is committed to delivering high-quality solutions, fostering collaborative relationships, and continuously improving its products and services.

Analitičari trenutno postavljaju prosečnu ciljanu cenu 18,50 USD za akciju Simulations Plus (medijana: 18,50 USD), što znači +0,0 % u odnosu na poslednju cenu. Konsenzus se zasniva na 12 ocena.

Simulations Plus Циљне цене аналитичара 2026

12 analitičara trenutno ocenjuje akciju Simulations Plus: 0 preporučuje kupovinu, 7 držanje i 5 prodaju. Za 2026 analitičari očekuju da Simulations Plus ostvari prihod 81,80 М USD i zaradu po akciji 0,82 USD.

Simulations Plus Циљне цене аналитичара 2026

Po trenutnom kursu akcija Simulations Plus kotira 16,60 EUR (18,50 USD).

Akcija Simulations Plus (SLP) kotira na 1 berze, uključujući: NASDAQ (SLP).

Simulations Plus Inc. is a leading company in the field of simulation technology and software development. It provides solutions for researchers and experts in various industries, including biotechnology, pharmaceuticals, agriculture, food technology, and more. The company offers a range of products and tools for data analysis and innovative strategy development to bring new products and applications to the market. Some of its notable products include PK-SIM, MoBi, ADMET Predictor, GastroPlus, DILIsym, and MedChem Studio. Simulations Plus also offers solutions for the agricultural sector, such as Cartagenia, Crop Laptop, and Dose Response Toxicology. The company provides training and support to its customers, aiming to optimize their business processes. Its business model focuses on processing and analyzing large data sets to provide relevant insights and support decision-making processes. Simulations Plus aims to expand into new markets and develop products based on the latest technological advancements.

očekivana prihod od Simulations Plus je 81,80 М USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

očekivana dobit od Simulations Plus je 16,48 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Simulations Plus je trenutno 22,69. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Simulations Plus.

Odnos cene i prihoda (KUV) za Simulations Plus je trenutno 4,57. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Simulations Plus.

Eulpool score kvaliteta za Simulations Plus je 3/10.

ISIN za Simulations Plus je US8292141053. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Simulations Plus je 924294. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Simulations Plus je SLP. Simbol tikera se koristi za trgovinu akcijama Simulations Plus na berzanskom tržištu.